Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Ariad Suspends Sales Of Cancer Pill Due To Blood Clots

By Pharmaceutical Processing | October 31, 2013

NEW YORK (AP) — Ariad Pharmaceuticals is suspending sales of its leukemia drug Iclusig because of concerns that patients could suffer from blood clots. The said Thursday that the Food and Drug Administration asked it to stop marketing the drug Wednesday afternoon. The company is negotiating with the FDA about changes to prescribing information and new ways to manage the risks associated with Iclusig. Ariad said it wants to resume marketing the drug.

Shares of Ariad Pharmaceuticals Inc. have lost three-quarters of their value, trading at their lowest level in three years, since concerns about side effects were disclosed earlier this month. The stock slid 43 percent to $2.24 in premarket trading Thursday. In December the FDA approved Iclusig as a treatment for two rare types of leukemia. It’s a daily pill and Ariad’s only approved product. It brought in $13.9 million in sales in the second quarter.

On October 9 the company disclosed a higher rate of side effects from Iclusig related to blood clots. Ariad said that after two years of research in a study, 11.8 percent of patients treated with the drug suffered a serious blood clot in an artery, worsening from the eight percent rate after 11 months. The FDA halted enrollment of patients in new studies, and on October 18 Ariad said it is ending a late-stage trial of the drug because of those side effects.

Related Articles Read More >

FDA logo
FDA prevented 317 drug shortages in 2021
Pfizer-BioNTech vaccine vial
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards